<?xml-stylesheet type="text/xsl" href="https://emersonexchange365.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Justifying New Tech Investment When the Plant Is Running Full&amp;#160;Out</title><link>/industries/lifesciences/b/life-sciences-blog/posts/justifying-new-tech-investment-when-the-plant-is-running-full-160-out</link><description>I wanted to share my guest post over at the PharmaEvolution.com blog, Justifying New Tech Investment When the Plant Is Running Full Out. It can often be challenging to justify investing in new technology when a plant has spare capacity, as Michalle Adkins</description><dc:language>en-US</dc:language><generator>Telligent Community 13</generator></channel></rss>